Search results
Gilead reviewing drug acquired in $5B buyout after latest setback
BioPharma Dive via Yahoo Finance· 3 months agoGilead Sciences is evaluating the future of a cancer drug acquired in a multibillion-dollar deal...
Gilead Sciences: The Bull Case Is More Powerful Than You Think
GuruFocus.com via Yahoo Finance· 5 months agoGilead Sciences Inc. (NASDAQ:GILD) is an American pharmaceutical company specializing in developing...
Gilead profit tops expectations despite lower COVID drug sales, outlook raised
Reuters via Yahoo Finance· 2 years agoGilead Sciences Inc on Thursday posted a higher-than-expected third-quarter profit on the back of...
Gilead posts quarterly loss on acquisition charge, revenue rises 5%
Reuters via Yahoo Finance· 3 weeks ago(Reuters) -Gilead Sciences reported a first-quarter loss on Thursday after taking a $3.9 billion...
CymaBay Rockets After Gilead Snaps Up The Liver-Focused Biotech For $4.3 Billion
Investor's Business Daily· 3 months agoCymaBay stock rocketed more than 25% Monday after Gilead Sciences said it would snap up the liver...
Why Gilead Sciences Stock Dropped Today
Motley Fool via Yahoo Finance· 3 months agoShares of Gilead Sciences (NASDAQ: GILD) are down 3.7% as of 3:30 p.m. ET Wednesday after the biopharmaceuticals giant announced mixed quarterly results...
Gilead quarterly results beat Street estimates as lower taxes boost profit
Reuters via Yahoo Finance· 6 months ago(Reuters) -Drugmaker Gilead Sciences on Tuesday said its third-quarter sales were little changed...
Gilead Beats Earnings Expectations After Rocky Quarter
Barrons.com· 3 weeks agoFEATURE After a sell off that saw its shares fall nearly 20% this year, the biotech Gilead Sciences...
Gilead to buy CymaBay in $4.3B deal for liver disease drug
BioPharma Dive via Yahoo Finance· 3 months agoThe proposed acquisition is a bet on CymaBay’s drug seladelpar, which is now under FDA review in a...
This New Drug Could Be Gilead Sciences' Growth Catalyst
Motley Fool· 1 year agoGilead Sciences (NASDAQ: GILD) has been a top stock to own this year, with its shares rising 17% and...
